177 related articles for article (PubMed ID: 9479873)
1. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 1997 Dec; 66(4):459-77. PubMed ID: 9479873
[TBL] [Abstract][Full Text] [Related]
2. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL
Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
5. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
6. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
7. Anticancer antifolates: current status and future directions.
McGuire JJ
Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
[TBL] [Abstract][Full Text] [Related]
8. Antifolate resistance and its circumvention by new analogues.
Takemura Y; Kobayashi H; Miyachi H
Hum Cell; 2001 Sep; 14(3):185-202. PubMed ID: 11774738
[TBL] [Abstract][Full Text] [Related]
9. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of resistance to antifolates, a review.
Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
[TBL] [Abstract][Full Text] [Related]
12. Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H
Anticancer Drugs; 1999 Aug; 10(7):677-83. PubMed ID: 10507318
[TBL] [Abstract][Full Text] [Related]
13. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2008 Feb; 8(2):205-31. PubMed ID: 18288923
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.
Gangjee A; Jain HD; Kurup S
Anticancer Agents Med Chem; 2007 Sep; 7(5):524-42. PubMed ID: 17896913
[TBL] [Abstract][Full Text] [Related]
16. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
Senkovich O; Schormann N; Chattopadhyay D
Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
[TBL] [Abstract][Full Text] [Related]
17. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
18. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
19. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method.
Rots MG; Willey JC; Jansen G; Van Zantwijk CH; Noordhuis P; DeMuth JP; Kuiper E; Veerman AJ; Pieters R; Peters GJ
Leukemia; 2000 Dec; 14(12):2166-75. PubMed ID: 11187907
[TBL] [Abstract][Full Text] [Related]
20. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Cancer Lett; 1995 Jan; 88(1):93-9. PubMed ID: 7850779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
